What does EXOTHERA do?

EXOTHERA is registered with the CBE as active in: Vervaardiging van geneesmiddelen. Public Limited, started on 2 March 2020, 5 establishments.

What is the address of EXOTHERA?

The registered office of EXOTHERA is located at Zoning de Jumet,avenue Centrale 52, 6040 Charleroi.

Is EXOTHERA still active?

No. The CBE lists EXOTHERA with legal situation “Opening faillissement”. The date of the court ruling is published in the Belgian Official Gazette; the register does not carry it.

Is EXOTHERA registered on Peppol?

No, EXOTHERA is currently not registered on the Peppol network.

What is the enterprise number of EXOTHERA?

The enterprise number of EXOTHERA is BE0744643660.

When was EXOTHERA founded?

EXOTHERA was founded on 2 March 2020.

Who are the directors of EXOTHERA?

According to the 2023 annual accounts, the directors of EXOTHERA are: Hugues BULTOT, BioPharma Management and Consulting, THE CLUB DEAL SA, Viva Finance SRL, CAHN CONSULT BV, ALERION BV, José CASTILLO, SAMANDA SA.

Is EXOTHERA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Opening faillissement according to the CBE, started on 2 March 2020; 3 annual accounts filed, latest fiscal year 2023; 9 directors known from the annual account; 5 establishments in the CBE.

How much profit did EXOTHERA make in 2023?

EXOTHERA recorded a loss after taxes of € 31,353,894 in financial year 2023.

What is the revenue of EXOTHERA?

In its most recent annual accounts (2023), EXOTHERA reported revenue of € 9,954,953.

How much does an employee at EXOTHERA earn?

The average wage cost per full-time employee at EXOTHERA was € 99,100 in 2023: staff costs of € 13.8 million for 139.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does EXOTHERA have?

According to the 2023 annual accounts, EXOTHERA has 139.2 full-time equivalents (FTE).

EXOTHERA (Public Limited) - Charleroi - BE0744643660

Dossier EXOTHERA, printed on 29 October 2026 from databakkes.be/en/0744643660/exothera. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2022 and 2023.
Tight liquidity NBB

Cash and receivables cover 38 % of short-term debt in 2023; threshold 65 %.
Legal situation KBO

Opening faillissement according to the CBE.

Financials

Financial year 2023

EXOTHERA from Charleroi, company number BE0744643660, closed financial year 2023 with a result of € -31.4 million after tax. For that financial year EXOTHERA recorded revenue of € 10 million and equity of € 4.6 million. Compared with financial year 2022, the result moved from € -23 million to € -31.4 million. The company made a loss. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 4, 2024.

What it is worth Growing

€ 4.6 million

▲ 22% vs 2022

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -31.4 million

▼ 36 % more loss than in 2022

Profit after tax over the fiscal year.

Cash in the bank

€ 2.3 million

▲ 30% vs 2022

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -8.5 million.

People and assets in 2023

Full-time equivalents

139.2

▲ 5.9 vs 2022

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 11.4 million in 2023, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 13.8 million

▲ 13% vs 2022

€ 99,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 6.4 million

▲ 10% vs 2022

Of which on lease € 6.3 million.

Debts at end 2023

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 5.7 million

▼ 7% vs 2022

€ 1.4 million is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 13.5 million

▲ 33% vs 2022

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 305 days on average.

Taxes and wages

€ 2.5 million

▼ 5% vs 2022

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	Change 2022 → 2023
Revenue	€ 4,169,181 Revenue 2021: € 4,169,181 First fiscal year in the series	€ 7,135,834 Revenue 2022: € 7,135,834 ▲ 71% vs 2021 (€ 4,169,181) Favourable step	€ 9,954,953 Revenue 2023: € 9,954,953 ▲ 40% vs 2022 (€ 7,135,834) Favourable step	▲ 40%
Profit after taxes	€ -11,411,198 Profit after taxes 2021: € -11,411,198 First fiscal year in the series	€ -22,975,304 Profit after taxes 2022: € -22,975,304 ▼ € 11.6 million vs 2021 (€ -11,411,198) Unfavourable step	€ -31,353,894 Profit after taxes 2023: € -31,353,894 ▼ € 8.4 million vs 2022 (€ -22,975,304) Unfavourable step	▼ € 8.4 million
Equity	€ 2,786,882 Equity 2021: € 2,786,882 First fiscal year in the series	€ 3,798,443 Equity 2022: € 3,798,443 ▲ 36% vs 2021 (€ 2,786,882) Favourable step	€ 4,642,084 Equity 2023: € 4,642,084 ▲ 22% vs 2022 (€ 3,798,443) Favourable step	▲ 22%
Total debts	€ 18,018,911 Total debts 2021: € 18,018,911 First fiscal year in the series	€ 25,354,123 Total debts 2022: € 25,354,123 ▲ 41% vs 2021 (€ 18,018,911) Unfavourable step	€ 31,008,330 Total debts 2023: € 31,008,330 ▲ 22% vs 2022 (€ 25,354,123) Unfavourable step	▲ 22%
Cash	€ 726,811 Cash 2021: € 726,811 First fiscal year in the series	€ 1,779,958 Cash 2022: € 1,779,958 ▲ 145% vs 2021 (€ 726,811) Favourable step	€ 2,313,505 Cash 2023: € 2,313,505 ▲ 30% vs 2022 (€ 1,779,958) Favourable step	▲ 30%
Retained profit	€ -3,599,058 Retained profit 2021: € -3,599,058 First fiscal year in the series	€ -6,714,136 Retained profit 2022: € -6,714,136 ▼ € 3.1 million vs 2021 (€ -3,599,058) Unfavourable step	€ -8,521,139 Retained profit 2023: € -8,521,139 ▼ € 1.8 million vs 2022 (€ -6,714,136) Unfavourable step	▼ € 1.8 million
Bank debt	€ 2,332,854 Bank debt 2021: € 2,332,854 First fiscal year in the series	€ 6,064,439 Bank debt 2022: € 6,064,439 ▲ 160% vs 2021 (€ 2,332,854) Unfavourable step	€ 5,668,578 Bank debt 2023: € 5,668,578 ▼ 7% vs 2022 (€ 6,064,439) Favourable step	▼ 7%
Balance sheet total	€ 20,805,794 Balance sheet total 2021: € 20,805,794 First fiscal year in the series	€ 29,152,566 Balance sheet total 2022: € 29,152,566 ▲ 40% vs 2021 (€ 20,805,794) Unchanged	€ 35,650,414 Balance sheet total 2023: € 35,650,414 ▲ 22% vs 2022 (€ 29,152,566) Unchanged	▲ 22%
Employees (FTE)	84 Employees (FTE) 2021: 84 First fiscal year in the series	133.3 Employees (FTE) 2022: 133.3 ▲ 49.3 vs 2021 (84) Unchanged	139.2 Employees (FTE) 2023: 139.2 ▲ 5.9 vs 2022 (133.3) Unchanged	▲ 5.9

Key figures of EXOTHERA, fiscal years 2021 to 2023, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2024 has not been filed yet; it was expected before 31 July 2025.

What happened to EXOTHERA?

What happened at EXOTHERA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

EXOTHERA is active according to the CBE. Legal situation: Opening faillissement.

2029 Viva Finance SRL stepped down as director. NBB
2029 ALERION BV stepped down as director. NBB
2027 ANTROBUS SRL stepped down as director. NBB
2026 Hugues BULTOT stepped down as director. NBB
2026 José CASTILLO stepped down as director. NBB
Jul 4, 2024 New annual accounts for financial year 2023: loss of € 31.4 million. Source: NBB ↗
2024 Viva Finance SRL became a director. NBB
2024 ALERION BV became a director. NBB